At Siludi Pharmaceutical's 2026 interim report performance exchange meeting, Gong Zhaolong, Chairman and CEO of Siludi Pharmaceutical, said that in the next 3-5 years, the company will focus on a number of key sectors: one is to lay out tumor vaccines and prevent recurrence and metastasis to provide full immune protection for people with recurrence and high risk progression after surgery to fill the treatment gap in clinical prevention of recurrence and metastasis; the second is to deeply cultivate the RDC field. On the basis of first-generation beta rays, the company will further lay out alpha rays and other next-generation technologies. Currently, the company has completed construction covering molecular design, targeting, and drug screening Physical verification and pre-clinical synthesis The evaluation's integrated RDC full-link R&D system; the third is to build an AI-driven LNP-mRNA technology platform, lay out a cutting-edge CGT race track, focus on tumor recurrence scenarios, and build competitive barriers for differentiated mRNA technology.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.